Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome

Autor:	George Frimpong Boafo, Zhongjian Chen, Marwa Ahmed Sallam, Qingqing Xiao, Makhloufi Zoulikha, Wei He
Rok vydání:	2021
Předmět:	Small interfering RNA ARDS DOTAP 1 2-dioleoyl-3-trimethylammonium-propane IFN interferons Review CS cigarette smoke TNF-α tumor necrosis factor-α MIF macrophage migration inhibitory factor AAV adeno-associated virus General Pharmacology Toxicology and Pharmaceutics AV adenovirus dsDNA double-stranded DNA DODAP 1 2-dioleyl-3-dimethylammonium-propane AM alveolar macrophage pDNA plasmid DNA PS pulmonary surfactant EpiC epithelial cell RNAi RNA interference Mrna level HMGB1 high-mobility group box 1 NETs neutrophil extracellular traps SNALP stable nucleic acid lipid particle VILI ventilator-induced lung injury DODMA 1 2-dioleyloxy-N N-dimethyl-3-aminopropane ALI/ARDS PF pulmonary fibrosis HNPs hybrid nanoparticles PAMPs pathogen-associated molecular patterns DDAB dimethyldioctadecylammonium bromide TGF-β transforming growth factor-β DAMPs danger-associated molecular patterns HALI hyperoxic acute lung injury NPs nanoparticles PDGFRα platelet-derived growth factor receptor-α PEG polyethylene glycol PEI polyethyleneimine VALI ventilator-associated lung injury EC endothelial cell CPP cell-penetrating peptide ATII alveolar cell type II medicine.disease PMs polymeric micelles DOPC 1 2-dioleoyl-sn-glycero-3-phosphocholine PD-L1 programmed death ligand-1 COPD chronic obstructive pulmonary disease HMVEC human primary microvascular endothelial cell siRNA small interfering RNA siRNA ALI/ARDS acute lung injury/acute respiratory distress syndrome EPC egg phosphatidylcholine Nanoparticles LPS lipopolysaccharides N/P ratio nitrogen /phosphate ratio Chemokine PRR pattern recognition receptor EXOs exosomes DOPE 1 2-dioleoyl-L-α-glycero-3-phosphatidylethanolamine PEEP positive end-expiratory pressure ICAM-1 intercellular adhesion molecule-1 Inflammatory diseases Hem-CLP hemorrhagic shock followed by cecal ligation and puncture septic challenge Bioinformatics SLN solid lipid nanoparticle Cellular uptake miRNA microRNA RISC RNA-induced silencing complex NF-κB nuclear factor kappa B PLGA poly(D L-lactic-co-glycolic acid) biology FDA US Food and Drug Administration Ago-2 argonaute 2 DPPC 1 2-dipalmitoyl-sn-glycero-3-phosphocholine PAMAM polyamidoamine Endosomal escape mRNA messenger RNA medicine.anatomical_structure PAI-1 plasminogen activator inhibitor-1 shRNA short RNA DC-Chol 3β-(N-(N’ N’-dimethylethylenediamine)-carbamoyl) cholesterol Drug delivery DOSPA 2 3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N N-dimethyl-1-propanaminium TLR Toll-like receptor PFC perfluorocarbon Acute respiratory distress Lung injury DPI dry powder inhaler eggPG L-α-phosphatidylglycerol ROS reactive oxygen species medicine Pulmonary administration DOTMA N-[1-(2 3-dioleoyloxy)propyl]-N N N-trimethylammonium Lung business.industry MEND multifunctional envelope-type nano device CFDA China Food and Drug Administration ATI alveolar cell type I RIP2 receptor-interacting protein 2 Myd88 myeloid differentiation primary response 88 biology.protein dsRNA double-stranded RNA CXCR4 C-X-C motif chemokine receptor type 4 business DOGS dioctadecyl amido glycin spermine
Zdroj:	Acta Pharmaceutica Sinica. B
ISSN:	2211-3835
Popis:	The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of several unmet medical needs, including acute lung injury/acute respiratory distress syndrome (ALI/ARDS) wherein siRNA may be implemented to modify the expression of pro-inflammatory cytokines and chemokines at the mRNA level. The clear anatomy, accessibility, and relatively low enzyme activity make the lung a good target for local siRNA therapy. However, the clinical translation of siRNA is hampered by the inefficient delivery of siRNA therapeutics to the target cells due to the properties of naked siRNA. Thus, this review will focus on the various delivery systems that can be used and the different barriers that need to be surmounted for the development of stable inhalable siRNA formulations for human use before siRNA therapeutics for ALI/ARDS become available in the clinic. Graphical abstract The pulmonary administration of siRNA in an appropriate delivery vector seems promising to treat undruggable lung diseases such as acute lung injury/acute respiratory distress syndrome ALI/ARDS.Image 1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa9513250ae8817b12d84c4264ed5c97 https://pubmed.ncbi.nlm.nih.gov/34401226 Zobrazit plný text záznamu